Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TSHA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTaysha Gene Therapies holds routine annual meeting, elects directors and ratifies auditor
Filed June 2, 2026 · Period ending June 1, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved executive compensation with 82% support, though 18% voted against, suggesting some concern about pay levels or structure at the gene therapy company.
Item 5.07: Say-on-pay vote verify on EDGAR → -
low
Sean P. Nolan and Laura Sepp-Lorenzino elected to board for three-year terms through 2029. Sepp-Lorenzino received 27% withheld votes, higher than typical but not unusual for biotech boards.
Item 5.07: Director elections verify on EDGAR → -
low
Deloitte & Touche ratified as auditor for 2026 with 99.98% approval, indicating no shareholder concerns about financial reporting quality.
Item 5.07: Auditor ratification verify on EDGAR → -
low
Shareholders voted 99.5% in favor of annual say-on-pay votes going forward, establishing yearly executive compensation reviews.
Item 5.07: Say-on-pay frequency verify on EDGAR →
Summary
Taysha Gene Therapies completed its 2026 annual meeting with 84.86% shareholder attendance, conducting standard corporate governance business. The company re-elected two directors to three-year terms and ratified its auditor selection with overwhelming support.
The most notable result was the say-on-pay vote, where executive compensation received 82% approval—passing comfortably but with 18% opposition that suggests a meaningful minority of shareholders have concerns about how executives are paid. For retail investors, this filing is purely procedural with no immediate business impact.
The company remains on its existing strategic path with the same leadership team and auditor. The elevated opposition to executive pay is worth monitoring in future proxy statements to see if the board adjusts compensation practices. Watch for the next quarterly earnings report or clinical trial updates for material news about Taysha's gene therapy pipeline and cash runway.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Taysha held its 2026 annual meeting with 84.86% attendance, electing two directors and ratifying auditor selection.
Added in current filing · verify on EDGAR →
Proposal No. 3: Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For | Votes Against | Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 | 36,396,784 | 345,291
Shareholders approved executive compensation on a non-binding advisory basis with 168,142,551 votes for versus 36,396,784 against. While the proposal passed, approximately 17.8% of votes cast were against the compensation package, indicating some shareholder concern about executive pay levels or structure.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
Proposal No. 1: Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name | Votes For | Votes Withheld Sean P. Nolan 169,142,295 | 35,742,331 | Laura Sepp-Lorenzino, Ph.D. | 150,094,517 | 54,790,109 | Broker Non-Votes: 38,973,186 | Both nominees were elected.
Shareholders elected Sean P. Nolan and Laura Sepp-Lorenzino to serve as directors until the 2029 annual meeting. Nolan received 169,142,295 votes for with 35,742,331 withheld, while Sepp-Lorenzino received 150,094,517 votes for with 54,790,109 withheld. Both nominees secured sufficient votes for election.
Added in current filing · verify on EDGAR →
Proposal No. 2: Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For | Votes Against | Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 | 25,551 | 18,176
Shareholders overwhelmingly ratified the selection of Deloitte & Touche LLP as the company's independent auditor for fiscal year 2026. The proposal received 243,814,085 votes in favor with only 25,551 against and 18,176 abstentions, representing near-unanimous approval.
Added in current filing · verify on EDGAR →
Proposal No. 4: Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year | Two | Years | Three | Years | Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 | 360,924 | 630,378 | 67,607 | Broker Non-Votes: 38,973,186 Consistent with the stockholder voting results above and the recommendation of the board of directors of the Company (the “Board”) as disclosed in the Proxy Statement for the Annual Meeting, the Company has determined to solicit a non-binding advisory vote on the compensation of the Company’s named executive officers every year until the next required stockholder vote on the frequency of such non-binding advisory vote, or until the Board of the Company determines that a different frequency of such non-binding advisory vote is in the best interest of the Company’s stockholders.
Shareholders overwhelmingly preferred annual say-on-pay votes, with 203,825,717 votes for one year versus only 360,924 for two years and 630,378 for three years. The company confirmed it will hold annual advisory votes on executive compensation going forward, consistent with both shareholder preference and board recommendation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify